These Analysts Revise Their Forecasts On Thermo Fisher Scientific Following Upbeat Earnings
These Analysts Revise Their Forecasts On Thermo Fisher Scientific Following Upbeat Earnings
Thermo Fisher Scientific Inc. (NYSE:TMO) reported better-than-expected first-quarter financial results and raised its FY24 guidance on Wednesday.
賽默飛世爾科學公司（紐約證券交易所代碼：TMO）公佈的第一季度財務業績好於預期，並在週三上調了其24財年的預期。
Thermo Fisher Scientific posted a first-quarter revenue of $10.34 billion, down 3% year over year, beating the consensus of $10.17 billion. Adjusted EPS of $5.11 beat the consensus of $4.71 and grew from $5.03 a year ago, according to data from Benzinga Pro.
賽默飛世爾科學公佈的第一季度收入爲103.4億美元，同比下降3％，超過了預期的101.7億美元。根據Benzinga Pro的數據，調整後的每股收益爲5.11美元，超過了預期的4.71美元，高於去年同期的5.03美元。
Revenue from the Life Sciences Solutions Segment declined by 12.5% to $2.29 billion. Analytical Instruments Segment sales were down 2.1% to $1.69 billion. Specialty Diagnostics Segment revenues were almost flat at $1.1 billion, and Laboratory Products and Biopharma Services segment sales were down 0.7% to $5.72 billion.
生命科學解決方案板塊的收入下降了12.5％，至22.9億美元。分析儀器板塊的銷售額下降了2.1％，至16.9億美元。專業診斷板塊收入幾乎持平，爲11億美元，實驗室產品和生物製藥服務板塊的銷售額下降0.7％，至57.2億美元。
"We had a great start to the year, driven by our proven growth strategy and the impact of our PPI Business System. Our team continues to enable the success of our customers while demonstrating incredibly strong commercial execution and operational discipline. This positions us to deliver differentiated performance in 2024 as we continue to create value for all of our stakeholders and build an even brighter future for our company," said Marc Casper, chairman, president, and CEO.
“在我們行之有效的增長戰略和PPI業務系統的影響下，我們今年有了一個良好的開端。我們的團隊繼續推動客戶取得成功，同時表現出極強的商業執行和運營紀律。這使我們能夠在2024年實現差異化業績，因爲我們將繼續爲所有利益相關者創造價值，爲公司建設更光明的未來。” 董事長、總裁兼首席執行官馬克·卡斯珀說。
Thermo Fisher boosted its 2024 sales guidance to $42.3 billion—$43.3 billion, compared to its previous guidance of $42.1 billion—$43.3 billion and consensus of $42.83 billion. The company increased its adjusted EPS guidance to $21.14-$22.02 versus its previous guidance of $20.95-$22.00 and consensus of $21.53.
賽默飛世爾將其2024年的銷售預期提高至423億美元至433億美元，而之前的預期爲421億美元至433億美元，共識爲428.3億美元。該公司將調整後的每股收益預期上調至21.14美元至22.02美元，而之前的預期爲20.95-22.00美元，共識爲21.53美元。
Thermo Fisher Scientific shares rose 0.5% to close at $577.39 on Wednesday.
賽默飛世爾科學股價週三上漲0.5％，收於577.39美元。
These analysts made changes to their price targets on Thermo Fisher Scientific following earnings announcement.
業績公佈後，這些分析師調整了賽默飛世爾科學的目標股價。
- Baird cut the price target on Thermo Fisher Scientific from $621 to $620. Baird analyst Catherine Schulte maintained an Outperform rating.
- JP Morgan boosted the price target on Thermo Fisher Scientific from $600 to $650. JP Morgan analyst Tycho Peterson maintained an Overweight rating.
- 貝爾德將賽默飛世爾科學的目標股價從621美元下調至620美元。貝爾德分析師凱瑟琳·舒爾特維持跑贏大盤的評級。
- 摩根大通將賽默飛世爾科學的目標股價從600美元上調至650美元。摩根大通分析師泰科·彼得森維持增持評級。
Read More: Jim Cramer: You're 'Dice Rolling' With This Biopharma Stock, But Vista Energy Is 'A Good Situation'
閱讀更多：吉姆·克萊默：這隻生物製藥股票你正在 “擲骰子”，但是 Vista Energy 是 “好情況”
譯文內容由第三人軟體翻譯。